JP2010518871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518871A5 JP2010518871A5 JP2009551284A JP2009551284A JP2010518871A5 JP 2010518871 A5 JP2010518871 A5 JP 2010518871A5 JP 2009551284 A JP2009551284 A JP 2009551284A JP 2009551284 A JP2009551284 A JP 2009551284A JP 2010518871 A5 JP2010518871 A5 JP 2010518871A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- fusion polypeptide
- domain
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 230000004927 fusion Effects 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 239000004480 active ingredient Substances 0.000 claims 7
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 6
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 108091008605 VEGF receptors Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 4
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 3
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 3
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 206010003445 Ascites Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- RRAWMVYBOLJSQT-ABZYKWASSA-N (2r,3s)-5-[6-amino-8-(pyren-2-ylamino)purin-9-yl]-2-(hydroxymethyl)oxolan-3-ol Chemical compound C=1C(C2=C34)=CC=C3C=CC=C4C=CC2=CC=1NC1=NC=2C(N)=NC=NC=2N1C1C[C@H](O)[C@@H](CO)O1 RRAWMVYBOLJSQT-ABZYKWASSA-N 0.000 claims 1
- 102000009840 Angiopoietins Human genes 0.000 claims 1
- 108010009906 Angiopoietins Proteins 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 102000012545 EGF-like domains Human genes 0.000 claims 1
- 108050002150 EGF-like domains Proteins 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89176907P | 2007-02-27 | 2007-02-27 | |
| US60/891,769 | 2007-02-27 | ||
| PCT/IB2008/000901 WO2008132568A2 (en) | 2007-02-27 | 2008-02-27 | Fusion proteins binding to growth factors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014042371A Division JP5952847B2 (ja) | 2007-02-27 | 2014-03-05 | 成長因子と結合する融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518871A JP2010518871A (ja) | 2010-06-03 |
| JP2010518871A5 true JP2010518871A5 (enExample) | 2011-04-14 |
| JP5564268B2 JP5564268B2 (ja) | 2014-07-30 |
Family
ID=39795468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009551284A Active JP5564268B2 (ja) | 2007-02-27 | 2008-02-27 | 成長因子と結合する融合タンパク質 |
| JP2014042371A Active JP5952847B2 (ja) | 2007-02-27 | 2014-03-05 | 成長因子と結合する融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014042371A Active JP5952847B2 (ja) | 2007-02-27 | 2014-03-05 | 成長因子と結合する融合タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10259860B2 (enExample) |
| EP (1) | EP2126092B1 (enExample) |
| JP (2) | JP5564268B2 (enExample) |
| KR (1) | KR101220245B1 (enExample) |
| CN (2) | CN108546301B (enExample) |
| AU (1) | AU2008243928B2 (enExample) |
| CA (1) | CA2679658C (enExample) |
| DK (1) | DK2126092T3 (enExample) |
| ES (1) | ES2688623T3 (enExample) |
| IL (1) | IL200593B (enExample) |
| WO (1) | WO2008132568A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10259860B2 (en) * | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| CN101965406A (zh) | 2008-01-03 | 2011-02-02 | 斯克里普斯研究院 | 通过模块识别结构域的抗体靶向 |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| SG175004A1 (en) | 2009-04-02 | 2011-11-28 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| DK2417156T3 (en) | 2009-04-07 | 2015-03-02 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| NZ701769A (en) | 2009-09-16 | 2016-06-24 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| RU2607038C2 (ru) | 2011-02-28 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Антигенсвязывающие белки |
| CN103403025B (zh) | 2011-02-28 | 2016-10-12 | 弗·哈夫曼-拉罗切有限公司 | 单价抗原结合蛋白 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CN102219859B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| JP2014531424A (ja) | 2011-08-31 | 2014-11-27 | インディ モレキュラー，インコーポレイテッド | Ｖｅｇｆ−特異的捕捉剤、組成物、並びに使用及び製造方法 |
| RU2644341C2 (ru) | 2012-02-10 | 2018-02-08 | Дженентек, Инк. | Одноцепочечные антитела и другие гетеромультимеры |
| EP2867254B1 (en) | 2012-06-27 | 2017-10-25 | F. Hoffmann-La Roche AG | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| MX354862B (es) | 2012-06-27 | 2018-03-23 | Hoffmann La Roche | Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes. |
| RS62509B1 (sr) | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| GB201223053D0 (en) | 2012-12-20 | 2013-02-06 | Medical Res Council | Receptor |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| KR102060187B1 (ko) | 2013-07-19 | 2019-12-27 | 삼성전자주식회사 | Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도 |
| EP2832746B1 (en) | 2013-07-29 | 2018-07-18 | Samsung Electronics Co., Ltd | Anti-Ang2 antibody |
| KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
| RU2016115866A (ru) | 2013-10-11 | 2017-11-16 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи |
| KR20150063728A (ko) * | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | 항 VEGF-C/항 Ang2 이중 특이 항체 |
| KR101819135B1 (ko) * | 2014-03-18 | 2018-01-18 | 한국과학기술원 | 당화 vegf 디코이 수용체 융합 단백질 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性抗体 |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| CN109310756B (zh) * | 2016-05-13 | 2022-06-28 | 奥美药业有限公司 | 新型血管生成素2，vegf双特异性拮抗剂 |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CN112912104A (zh) * | 2018-08-17 | 2021-06-04 | 三钰生物科技股份有限公司 | 抗血管新生融合蛋白及其用途 |
| EP3856245A4 (en) * | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| BR112021007946A2 (pt) | 2018-10-29 | 2021-08-03 | F. Hoffmann-La Roche Ag | formulação de anticorpo |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| EP4524236A3 (en) * | 2019-12-06 | 2025-07-23 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
| KR102426802B1 (ko) * | 2019-12-23 | 2022-07-28 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물 |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| CN117255809B (zh) * | 2021-03-31 | 2025-05-30 | 杭州嘉因生物科技有限公司 | 靶向vegf和血管生成素的融合分子及其用途 |
| CA3228501A1 (en) * | 2021-08-09 | 2023-02-16 | Sicong DONG | Bispecific fusion polypeptide and application thereof |
| KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| CN114262683B (zh) * | 2022-03-01 | 2022-06-17 | 中国科学院动物研究所 | 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用 |
| WO2023199951A1 (ja) * | 2022-04-13 | 2023-10-19 | 株式会社セルージョン | 抗ｖｅｇｆ機能を有する多能性幹細胞及びその分化細胞 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169939A (en) * | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US6521424B2 (en) * | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
| DE60135633D1 (de) * | 2000-02-10 | 2008-10-16 | Massachusetts Eye & Ear Infirm | Photodynamische therapie zur behandlung von augenerkrankungen |
| PT1292335E (pt) * | 2000-06-23 | 2007-08-13 | Bayer Schering Pharma Ag | Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii) |
| EP1427829A4 (en) | 2001-08-31 | 2005-10-12 | Abmaxis Inc | MULTIVALENT PROTEIN CONJUGATE WITH SEVERAL LIGANDEN BINDING RECORDORDOMAS |
| US7081443B2 (en) * | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
| US7700318B2 (en) * | 2004-08-25 | 2010-04-20 | Amprotein Corporation | Chimeric polypeptide and use thereof |
| KR20080022539A (ko) | 2004-10-12 | 2008-03-11 | 앰프로틴 코포레이션 | 키메라 단백질 |
| US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| US10259860B2 (en) * | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| KR102060187B1 (ko) * | 2013-07-19 | 2019-12-27 | 삼성전자주식회사 | Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도 |
-
2007
- 2007-10-31 US US11/932,021 patent/US10259860B2/en active Active
-
2008
- 2008-02-27 CN CN201810332855.2A patent/CN108546301B/zh active Active
- 2008-02-27 DK DK08788817.8T patent/DK2126092T3/en active
- 2008-02-27 ES ES08788817T patent/ES2688623T3/es active Active
- 2008-02-27 JP JP2009551284A patent/JP5564268B2/ja active Active
- 2008-02-27 EP EP08788817.8A patent/EP2126092B1/en active Active
- 2008-02-27 KR KR1020097020284A patent/KR101220245B1/ko active Active
- 2008-02-27 AU AU2008243928A patent/AU2008243928B2/en active Active
- 2008-02-27 CA CA2679658A patent/CA2679658C/en active Active
- 2008-02-27 WO PCT/IB2008/000901 patent/WO2008132568A2/en not_active Ceased
- 2008-02-27 CN CN200880013111.9A patent/CN101679988B/zh active Active
-
2009
- 2009-08-26 IL IL200593A patent/IL200593B/en active IP Right Grant
-
2014
- 2014-03-05 JP JP2014042371A patent/JP5952847B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518871A5 (enExample) | ||
| Qi et al. | Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1 | |
| IL264057A (en) | Antibodies and vaccines for use in the treatment of ROR1 cancers and inhibition of metastases | |
| Schaefer et al. | Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies | |
| Xu et al. | Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system | |
| US20210040193A1 (en) | Anti-pd-1/anti-vegf natural antibody structure like heterodimeric form bispecific antibody and preparation thereof | |
| JP2011024595A5 (enExample) | ||
| CN112601544A (zh) | 人类抗cd47抗体及其用途 | |
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP6519090B2 (ja) | 血管内皮成長因子融合タンパク質 | |
| JP2017515460A5 (enExample) | ||
| RU2013140472A (ru) | Слитый белок антиангиогенного индуцирующего фактора и его применение | |
| CN105175545A (zh) | 一种抗vegf-抗pd-1双功能抗体及其应用 | |
| RU2016113757A (ru) | Комбинированная терапия на основе антител против человеческого csf-1r и антител против человеческого pd-l1 | |
| JP2014503189A5 (enExample) | ||
| JP2011137003A5 (enExample) | ||
| RU2015123032A (ru) | Иммунотерапия с применением связывающих агентов | |
| JP2014518615A5 (enExample) | ||
| FI3309176T3 (fi) | Immunoglobuliinin yksittäinen vaihteleva domeeni -vasta-aineita ox40l:ää vastaan, konstrukteja ja niiden terapeuttinen käyttö | |
| PH12013500410B1 (en) | Vegf-binding molecules | |
| JP2013538566A5 (enExample) | ||
| AU2018303254B2 (en) | Generating multispecific antibody mixtures and methods of uses thereof | |
| RU2013140184A (ru) | Fgf-r-fc слитый белок и его использование | |
| EP4303231A1 (en) | Bispecific antibody | |
| CN109705213B (zh) | 抗金黄色葡萄球菌毒素抗体及其用途 |